OA04. 06 PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA)
LAH Douma, CJ De Gooijer, V Noort, F Lalezari… - Journal of Thoracic …, 2022 - jto.org
Methods PEMMELA was a prospective single-center, single-arm, open-label, investigator-
initiated phase 2 trial of pembrolizumab (200 mg once every three weeks intravenously) plus
lenvatinib (20 mg orally once daily) in patients with MPM who progressed after
chemotherapy. Main eligibility criteria were age 18 years or older, histologically proven
MPM, Eastern Cooperative Oncology Group PS 0-1 and presence of measurable disease
according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version …
initiated phase 2 trial of pembrolizumab (200 mg once every three weeks intravenously) plus
lenvatinib (20 mg orally once daily) in patients with MPM who progressed after
chemotherapy. Main eligibility criteria were age 18 years or older, histologically proven
MPM, Eastern Cooperative Oncology Group PS 0-1 and presence of measurable disease
according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version …
以上显示的是最相近的搜索结果。 查看全部搜索结果